These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 29063139

  • 1. Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats.
    Lazenka ML, Moerke MJ, Townsend EA, Freeman KB, Carroll FI, Negus SS.
    Psychopharmacology (Berl); 2018 Jan; 235(1):203-213. PubMed ID: 29063139
    [Abstract] [Full Text] [Related]

  • 2. Effects of Selective and Mixed-Action Kappa and Delta Opioid Receptor Agonists on Pain-Related Behavioral Depression in Mice.
    Negus SS, St Onge CM, Lee YK, Li M, Rice KC, Zhang Y.
    Molecules; 2024 Jul 16; 29(14):. PubMed ID: 39064909
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Nalfurafine prevents 5'-guanidinonaltrindole- and compound 48/80-induced spinal c-fos expression and attenuates 5'-guanidinonaltrindole-elicited scratching behavior in mice.
    Inan S, Dun NJ, Cowan A.
    Neuroscience; 2009 Sep 29; 163(1):23-33. PubMed ID: 19524022
    [Abstract] [Full Text] [Related]

  • 5. Nalfurafine, a kappa opioid receptor agonist, inhibits scratching behavior secondary to cholestasis induced by chronic ethynylestradiol injections in rats.
    Inan S, Cowan A.
    Pharmacol Biochem Behav; 2006 Sep 29; 85(1):39-43. PubMed ID: 16919318
    [Abstract] [Full Text] [Related]

  • 6. Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates.
    Ko MC, Husbands SM.
    J Pharmacol Exp Ther; 2009 Jan 29; 328(1):193-200. PubMed ID: 18842704
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Quantification of observable behaviors induced by typical and atypical kappa-opioid receptor agonists in male rhesus monkeys.
    Huskinson SL, Platt DM, Brasfield M, Follett ME, Prisinzano TE, Blough BE, Freeman KB.
    Psychopharmacology (Berl); 2020 Jul 29; 237(7):2075-2087. PubMed ID: 32372348
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Nalfurafine, a G-Protein-Biased KOR (Kappa Opioid Receptor) Agonist, Enhances the Diuretic Response and Limits Electrolyte Losses to Standard-of-Care Diuretics.
    Meariman JK, Sutphen JC, Gao J, Kapusta DR.
    Hypertension; 2022 Feb 29; 79(2):379-390. PubMed ID: 34852633
    [Abstract] [Full Text] [Related]

  • 13. Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in κ opioid aversion.
    Liu JJ, Chiu YT, DiMattio KM, Chen C, Huang P, Gentile TA, Muschamp JW, Cowan A, Mann M, Liu-Chen LY.
    Neuropsychopharmacology; 2019 Apr 29; 44(5):939-949. PubMed ID: 30082888
    [Abstract] [Full Text] [Related]

  • 14. In vitro and in vivo pharmacological characterization of the main metabolites of nalfurafine hydrochloride.
    Nakao K, Togashi Y, Honda T, Momen S, Umeuchi H, Sakakibara S, Tanaka T, Okano K, Mochizuki H.
    Eur J Pharmacol; 2012 Nov 15; 695(1-3):57-61. PubMed ID: 22981641
    [Abstract] [Full Text] [Related]

  • 15. Nalfurafine suppresses pruritogen- and touch-evoked scratching behavior in models of acute and chronic itch in mice.
    Akiyama T, Carstens MI, Piecha D, Steppan S, Carstens E.
    Acta Derm Venereol; 2015 Feb 15; 95(2):147-50. PubMed ID: 24890341
    [Abstract] [Full Text] [Related]

  • 16. Effects of the δ opioid receptor agonist SNC80 on pain-related depression of intracranial self-stimulation (ICSS) in rats.
    Negus SS, Rosenberg MB, Altarifi AA, O'Connell RH, Folk JE, Rice KC.
    J Pain; 2012 Apr 15; 13(4):317-27. PubMed ID: 22424913
    [Abstract] [Full Text] [Related]

  • 17. Modulation of cocaine-related behaviors by low doses of the potent KOR agonist nalfurafine in male C57BL6 mice.
    Dunn A, Windisch K, Ben-Ezra A, Pikus P, Morochnik M, Erazo J, Reed B, Kreek MJ.
    Psychopharmacology (Berl); 2020 Aug 15; 237(8):2405-2418. PubMed ID: 32435819
    [Abstract] [Full Text] [Related]

  • 18. Preclinical Studies on Nalfurafine (TRK-820), a Clinically Used KOR Agonist.
    Zhou Y, Freeman K, Setola V, Cao D, Kaski S, Kreek MJ, Liu-Chen LY.
    Handb Exp Pharmacol; 2022 Aug 15; 271():137-162. PubMed ID: 33834276
    [Abstract] [Full Text] [Related]

  • 19. Comparison of Pharmacological Properties between the Kappa Opioid Receptor Agonist Nalfurafine and 42B, Its 3-Dehydroxy Analogue: Disconnect between in Vitro Agonist Bias and in Vivo Pharmacological Effects.
    Cao D, Huang P, Chiu YT, Chen C, Wang H, Li M, Zheng Y, Ehlert FJ, Zhang Y, Liu-Chen LY.
    ACS Chem Neurosci; 2020 Oct 07; 11(19):3036-3050. PubMed ID: 32897695
    [Abstract] [Full Text] [Related]

  • 20. The G-protein biased kappa opioid agonists, triazole 1.1 and nalfurafine, produce non-uniform behavioral effects in male rhesus monkeys.
    Huskinson SL, Platt DM, Zamarripa CA, Dunaway K, Brasfield M, Prisinzano TE, Blough BE, Freeman KB.
    Pharmacol Biochem Behav; 2022 Jun 07; 217():173394. PubMed ID: 35513117
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.